Taurx Therapeutics Ltd., a company advancing a potentially powerful prodrug of methylthioninium chloride for the potential prevention of neurodegenerative diseases, has closed a $135 million equity financing that will support completion and analysis of phase III trials of the tau aggregation inhibitor (TAI), called LMT-X, in Alzheimer's disease (AD) and frontotemporal dementia.